Literature DB >> 15630459

Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

Luisa M Villar1, María C Sádaba, Ernesto Roldán, Jaime Masjuan, Pedro González-Porqué, Noelia Villarrubia, Mercedes Espiño, José A García-Trujillo, Alfredo Bootello, José C Alvarez-Cermeño.   

Abstract

Oligoclonal IgM bands restricted to cerebrospinal fluid are an unfavorable prognostic marker in MS, the most common demyelinating disease of the CNS. We have attempted to identify the B cell subpopulation responsible for oligoclonal IgM secretion and the specificity of these bands. In addition, we explored the relationship between specificity and disease evolution. Intrathecal B cell subpopulations present in 29 MS patients with oligoclonal IgM bands and 52 without them were analyzed. A considerable increase in CD5(+) B lymphocytes was found in patients with oligoclonal IgM bands. These cells mostly secrete IgM antibodies recognizing nonproteic molecules. We also studied whether oligoclonal IgM bands present in cerebrospinal fluid of 53 MS patients were directed against myelin lipids. This was the case in most patients, with phosphatidylcholine being the most frequently recognized lipid. Disease course of 15 patients with oligoclonal IgM against myelin lipids and 33 patients lacking them was followed. Patients with anti-lipid IgM suffered a second relapse earlier, had more relapses, and showed increased disability compared with those without anti-lipid IgM. The presence of intrathecal anti-myelin lipid IgM antibodies is therefore a very accurate predictor of aggressive evolution in MS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15630459      PMCID: PMC539201          DOI: 10.1172/JCI22833

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

Review 1.  Role of natural and immune IgM antibodies in immune responses.

Authors:  M Boes
Journal:  Mol Immunol       Date:  2000-12       Impact factor: 4.407

2.  Cutting edge commentary: two B-1 or not to be one.

Authors:  Thomas L Rothstein
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

3.  The membrane attack complex of complement causes severe demyelination associated with acute axonal injury.

Authors:  Richard J Mead; Sim K Singhrao; James W Neal; H Lassmann; B Paul Morgan
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

Review 4.  B cells and antibodies in CNS demyelinating disease.

Authors:  A H Cross; J L Trotter; J Lyons
Journal:  J Neuroimmunol       Date:  2001-01-01       Impact factor: 3.478

5.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

6.  Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response.

Authors:  T Derfuss; R Gürkov; F Then Bergh; N Goebels; M Hartmann; C Barz; B Wilske; I Autenrieth; M Wick; R Hohlfeld; E Meinl
Journal:  Brain       Date:  2001-07       Impact factor: 13.501

7.  A sensitive and reproducible method for the detection of oligoclonal IgM bands.

Authors:  L M Villar; P González-Porqué; J Masjuán; J C Alvarez-Cermeño; A Bootello; G Keir
Journal:  J Immunol Methods       Date:  2001-12-01       Impact factor: 2.303

Review 8.  Origins and functions of B-1 cells with notes on the role of CD5.

Authors:  Robert Berland; Henry H Wortis
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

9.  Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates.

Authors:  R Dabby; L H Weimer; A P Hays; M Olarte; N Latov
Journal:  Neurology       Date:  2000-04-11       Impact factor: 9.910

10.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2002-07       Impact factor: 13.501

View more
  79 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

2.  Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis.

Authors:  P Perini; F Ranzato; M Calabrese; L Battistin; P Gallo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-30       Impact factor: 10.154

3.  Therapeutics to promote CNS repair: a natural human neuron-binding IgM regulates membrane-raft dynamics and improves motility in a mouse model of multiple sclerosis.

Authors:  Xiaohua Xu; Aleksandar Denic; Arthur E Warrington; Allan J Bieber; Moses Rodriguez
Journal:  J Clin Immunol       Date:  2012-09-19       Impact factor: 8.317

Review 4.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.

Authors:  Martin Stangel; Sten Fredrikson; Edgar Meinl; Axel Petzold; Olaf Stüve; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

5.  Multiple sclerosis: Oligoclonal bands--a useful tool to avoid MS misdiagnosis.

Authors:  José C Álvarez-Cermeño; Luisa M Villar
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

Review 6.  The role of B cells in the immunopathogenesis of multiple sclerosis.

Authors:  Tohid Gharibi; Zohreh Babaloo; Arezoo Hosseini; Faroogh Marofi; Abbas Ebrahimi-Kalan; Saeed Jahandideh; Behzad Baradaran
Journal:  Immunology       Date:  2020-05-10       Impact factor: 7.397

Review 7.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

8.  Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis.

Authors:  Keith Van Haren; Beren H Tomooka; Brian A Kidd; Brenda Banwell; Amit Bar-Or; Tanuja Chitnis; Silvia N Tenembaum; Daniela Pohl; Kevin Rostasy; Russell C Dale; Kevin C O'Connor; David A Hafler; Lawrence Steinman; William H Robinson
Journal:  Mult Scler       Date:  2013-04-23       Impact factor: 6.312

9.  Cerebrospinal fluid in multiple sclerosis.

Authors:  Kottil W Rammohan
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

10.  Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage.

Authors:  Ralf A Linker; Peter Brechlin; Sarah Jesse; Petra Steinacker; D H Lee; Abdul R Asif; Olaf Jahn; Hayrettin Tumani; Ralf Gold; Markus Otto
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.